ERBB2 and breast cancer: To the best of our knowledge, this is the first study to evaluate the efficacy of new anti‐HER2 therapeutic strategies in relation to HRs expression in metastatic BC patients, while making a clear distinction between patients with HER2‐positive BC that express both HRs, only one of them, or no HRs at all.